NCI Definition: A benign or malignant, primary or metastatic neoplasm that affects the brain, meninges, or spinal cord. Representative examples of primary neoplasms include astrocytoma, oligodendroglioma, ependymoma, and meningioma. Representative examples of metastatic neoplasms include carcinoma and leukemia. [1]

Central nervous system neoplasms most frequently harbor alterations in VHL, NF2, PTEN, KDR, and CDKN2B [2].

Most Commonly Altered Genes in Central Nervous System Neoplasm

VHL Mutation (germline), VHL Mutation, PTEN Mutation (somatic), PTEN Mutation (germline), and PTEN Mutation are the most common alterations in central nervous system neoplasm [2].

Top Alterations in Central Nervous System Neoplasm

Significant Genes in Central Nervous System Neoplasm





Disease Details

Neoplasm of the Central Nervous System, Neoplasm of Central Nervous System, Tumor of Central Nervous System, Tumor of the CNS, Neoplasm of CNS, Central Nervous System Tumor, CNS Neoplasm, CNS Tumor, Tumor of the Central Nervous System, Tumor of CNS
Solid Neoplasm
Ependymal Tumor, Malignant Central Nervous System Neoplasm, Mixed Glioma, Spinal Cord Neoplasm, Astrocytic Tumor, Oligodendroglial Tumor, Central Nervous System Hemangioblastoma, Benign Central Nervous System Neoplasm, Cauda Equina Neoplasm, Central Nervous System Melanocytic Neoplasm, Central Nervous System Mesenchymal Non-meningothelial Tumor, Epidural Spinal Canal Neoplasm, Meningeal Neoplasm, Central Nervous System Germ Cell Tumor, Intradural Extramedullary Spinal Canal Neoplasm, Intracranial Neoplasm, Neuronal and Mixed Neuronal-Glial Tumors, and Intraspinal Meningioma
OncoTree Name
OncoTree Code


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.